Rithuximab in steroid-resistant nephrotic syndrome

Phase 3

Recruiting

• Conditions: Condition 1: Nephrotic syndrome. Condition 2: Nephrotic syndrome with focal and segmental glomerular lesion.; Nephrotic syndrome; Nephrotic syndrome with focal and segmental glomerular lesions

• Registration Number: IRCT20150421021894N1
• Lead Sponsor: Zahedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 23 April 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Idiopathic nephrotic syndrome
Unresponsive to steroid, cyclophosphamide or mycophenolate mofetil therapy
Active infection
Leukopenia
Immune deficiency syndrome
Positive PPD test
estimated GFR<90mL/min/m2
Patients ages between 1 and 12 years

Exclusion Criteria

Secondary nephrotic syndrome
Lupus
Diabetic Nephropathy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ength of remission. Timepoint: 12 months. Method of measurement: Degree of proteinuria.

Secondary Outcome Measures

Name	Time	Method
Improved renal fnction. Timepoint: 12 months. Method of measurement: Measurement of glomerular filtration rate.